RAMB - Fevereiro 2017

eixeira

104

ssoc

ras

2017; 63(2):100-108

tations (signs, symptoms, physiological or pathological

changes, etc.) similar to disorders requiring treatment,

can be applied with any substance (natural or synthetic)

and at any dose (by massive or infinitesimal), provided

this principle of similarity is observed. Thus, conven-

tional drugs can be employed according to the homeo-

pathic premises provided they cause primary effects

(therapeutic, adverse or collateral effects) similar to the

totality of individual characteristic manifestations.

In this proposal,

27-33

we are suggesting the use of the

rebound effect of modern drugs in a curative manner,

administering ultra-diluted doses (dynamized medicines)

to patients of the drugs that cause a set of similar adverse

events in phases I-IV pharmacological clinical trials, pro-

posing to stimulate a homeostatic response of the organ-

ism against its own disorders.

To make this project possible, a

Homeopathic Materia

Medica of Modern Drugs

was elaborated, systematizing

all of the primary or pathogenic effects (therapeutic,

adverse and collateral effects) to 1,250 modern drugs

described in

The United States Pharmacopeia Dispensing In-

formation

(USPDI),

according to an anatomical and

functional distribution (systems or tracts) and in ac-

cordance with the dynamics used in the chapters of the

classic

Homeopathic Materia Medica

In order to facilitate the selection of the individual-

ized medicines according to the totality of manifestations

similar to the patient-disease binomial, an essential prem-

ise for the success of homeopathic treatment, the second

stage of the project involved the elaboration of a

Homeo-

pathic Repertory of Modern Drugs

where the pathogenetic

effects and their corresponding medicines are organized

in the same anatomical/functional distribution, following

the arrangement of the classic homeopathic repertories.

Titled

New Homeopathic Medicines: Use of Modern Drugs

According to the Principle of Similitude

this project is described

and systematized in three digital compendia

(Scientific

Basis of the Principle of Similitude in Modern Pharmacology, Ho-

meopathic Materia Medica of Modern Drugs

and

Homeopathic

Repertory of Modern Drugs)

provided on a bilingual site with

free access

(http://www.newhomeopathicmedicines.com

allowing the proposal to be known and applied by all in-

terested colleagues.

Exemplifying this possible ‘off label’ use of numerous

classes of modern drugs according to the principle of

therapeutic similarity, dozens of therapeutic drugs that

show increased blood pressure as primary effect (adalim-

umab, cyclosporine, dopamine and anti-inflammatory

drugs, among others) could be used homeopathically to

treat hypertension, provided that other primary or patho-

genetic effects of the drug present similarity with the set

of signs and symptoms of the individual patient. Respect-

ing this individualization of medicine, drugs that increase

blood glucose (amprenavir, corticotropin, diazoxide and

estrogens, and more) could be employed homeopathi-

cally to treat diabetes; drugs that cause inflammation of

the gastric mucosa (abacavir, anti-inflammatory drugs,

carbidopa and cilostazol, among others) could be employed

homeopathically to treat gastritis and gastric ulcers; med-

icines that cause immunosuppression (cyclosporins, cor-

ticoids and immunosuppressants, and more) could be

employed to stimulate the immune system of immunosup-

pressed patients; among others. Table 1 describes some

examples of possible applications of therapeutic similar-

ity with modern drugs in disorders, diseases and syndromes,

in accordance with the adverse events caused by such on

the various systems or tracts of individuals and described

in phase I-IV pharmacological clinical trials.

29,45

dynamized

estrogen

the

treatment

chronic

pelvic

pain

associated with

endometriosis

Endometriosis is a chronic inflammatory disease character-

ized by the implantation and proliferation of endometrial

tissue in extrauterine locations, causing chronic pelvic pain

that is difficult to control. As the main pathophysiological

aspect, it is worth mentioning that endometriosis is an

estrogen-dependent disease. Putting into practice the pro-

posal described above, we developed a clinical research

protocol to assess the effect of dynamized estrogen in the

treatment of endometriosis-associated pelvic pain (dys-

menorrhea, deep dyspareunia, non-cyclic pelvic pain, cyclic

bowel pain and/or cyclic urinary pain).

In the study of modern drugs according to the USPDI

and, consequently, in the

Homeopathic Repertory of Modern

Drugs

(Chapter “Female Genitalia”),

we find a description

of the specific pathological sign of endometriosis (“endo-

metrial proliferation or hyperplasia”) as an adverse event

in four classes of conventional drugs (systemic and vaginal

estrogens, tamoxifen and toremifene) (Table 2).

One of those drugs, “systemic estrogen,” presents a set

of adverse events (pathogenetic effects) that are quite sim-

ilar to the main manifestations of endometriosis syndrome

(endometrial proliferation, dysmenorrhea, dyspareunia,

abdominal pain, depression, anxiety, insomnia andmigraine,

among others) (Table 3), and was selected for the study

due to this particularity (individualization of the medicine).

In this randomized, double-blind and placebo con-

trolled trial (RCT), 50 patients with endometriosis, chron-

ic pelvic pain refractory to conventional hormone thera-